Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | New therapeutic directions in CTCL

Pierluigi Porcu • 19 Jul 2019
ICML 2019
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases T-Cell Lymphoma Mogamulizumab
MAVORIC

Cutaneous T-cell lymphoma (CTCL) therapy has experienced a boost in recent times, such as the MAVORIC trial that led to the approval of mogamulizumab (NCT01728805). Here, Pierluigi Porcu, MD, Sidney Kimmel Cancer Center – Jefferson Health, discusses new therapeutic directions in CTCL. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Pierluigi Porcu

HRQoL in patients with R/R CTCL treated with lacutamab in the TELLOMAK trial
5:21
HRQoL in patients with R/R CTCL treated with lacutamab in the TELLOMAK trial
Pierluigi Porcu • 9 Dec 2024
The current standard of care for CTCL
3:46
The current standard of care for CTCL
Pierluigi Porcu • 9 Dec 2024
Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD
2:49
Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD
Pierluigi Porcu • 16 Jun 2023
The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges
3:00
The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges
Pierluigi Porcu • 16 Jun 2023

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals